Arsenic exposure and cancer mortality in a US-based prospective cohort: The strong heart study

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 11, 2013, Pages 1944-1953

  García Esquinas, Esther ^a,c,j,k   Pollán, Marina ^j,k   Umans, Jason G ^f,g   Francesconi, Kevin A ^l   Goessler, Walter ^l   Guallar, Eliseo ^b,c,d   Howard, Barbara ^f,g   Farley, John ^h   Best, Lyle G ⁱ   Navas Acien, Ana ^a,b,c,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Departments of Medicine   (United States)

^e DEPARTMENT OF PATHOLOGY   (United States)

^f MEDSTAR RESEARCH INSTITUTE   (United States)

^g Delaware   (United States)

^h ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

ⁱ MISSOURI BREAKS INDUSTRIES RESEARCH INC   (United States)

^j INSTITUTO DE SALUD CARLOS III   (Spain)

^k CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^l UNIVERSITY OF GRAZ   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARSENIC; CREATININE; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; AMERICAN INDIAN; ANTIHYPERTENSIVE THERAPY; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; ENVIRONMENTAL EXPOSURE; ESOPHAGUS CANCER; FEMALE; HAZARD RATIO; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METHYLATION; MULTICENTER STUDY; PANCREAS CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK FACTOR; STOMACH CANCER; UNITED STATES; URINALYSIS; URINE;

AGED; ARIZONA; ARSENIC; ARSENIC POISONING; ENVIRONMENTAL EXPOSURE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS; NORTH DAKOTA; OKLAHOMA; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SOUTH DAKOTA; SURVIVAL ANALYSIS;

EID: 84882242646     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0234-T     Document Type: Article

References (54)

1. International Agency for Research on Cancer (IARC). Monographs on the evaluation of carcinogenic risks to humans. Some drinkingwater disinfectants and contaminants, including arsenic. 2004. Vol no 84. Available at: http://monographs.iarc.fr/ENG/Monographs/vol84/mono84.pdf.
2. Chen CJ, Kuo TL, Wu MM. Arsenic and cancers. Lancet 1988;1:414-5.
3. Kurokawa M, Ogata K, Idemori M, Tsumori S, Miyaguni H, Inoue S, et al. Investigation of skin manifestations of arsenicism due to intake of arsenic-contaminated groundwater in residents of Samta, Jessore, Bangladesh. Arch Dermatol 2001;137:102-3.
4. Smith AH, Goycolea M, Haque R, Biggs ML. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 1998;147:660-9.
5. Hopenhayn-Rich C, Biggs ML, Smith AH. Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina. Int J Epidemiol 1998;27:561-9.
6. Stueckle TA, Lu Y, Davis ME, Wang L, Jiang BH, Holskova I, et al. Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol 2012;261:204-16.
7. Tokar EJ, Benbrahim-Tallaa L, Ward JM, Lunn R, Sams RL, Waalkes MP, et al. Cancer in experimental animals exposed to arsenic and arsenic compounds. Crit Rev Toxicol 2010;40:912-27.
8. Liu J, Waalkes MP. Liver is a target of arsenic carcinogenesis. Toxicol Sci 2008;105:24-32.
9. Bredfeldt TG, Jagadish B, Eblin KE, Mash EA, Gandolfi AJ. Monomethylarsonous acid induces transformation of human bladder cells. Toxicol Appl Pharmacol 2006;216:69-79.
10. Benbrahim-Tallaa L, Waalkes MP. Inorganic arsenic and human prostate cancer. Environ Health Perspect 2008;116:158-64.
11. Jackson BP, Taylor VF, Karagas MR, Punshon T, Cottingham KL. Arsenic, organic foods, and brown rice syrup. Environ Health Perspect 2012;120:623-6.
12. European Food Safety Authority (EFSA) and EFSA Panel on Contaminants in the Food Chain (CONTAM). Arsenic in food. EFSA J 2009; 7:1351.
13. US Environmental Protection Agency (EPA). 1992. Revised in 2012. Arsenic compounds. Available from: http://www.epa.gov/ttn/atw/hlthef/arsenic.html.
14. World Health Organization (WHO). Guidelines for drinking water quality. 1993. Revised in 2012. Volume no 1. Available at: http://www.who.int/water- sanitation-health/dwq/fulltext.pdf.
15. Smith AH. Arsenic Health Effects Research Program. Is the proposed new arsenic water standard of 10 ug/L sufficiently protective of public health? Available from: http://wwwbrr.cr.usgs.gov/projects/GWC-chemtherm/FinalAbsPDF/ smith.pdf.
16. Cantor KP, Lubin JH. Arsenic, internal cancers, and issues in inference from studies of low-level exposures in human populations. Toxicol Appl Pharmacol 2007;222:252-7.
17. Yorifuji T, Tsuda T, Doi H, Grandjean P. Cancer excess after arsenic exposure from contaminated milk powder. Environ Health Prev Med 2011;16:164-70.
18. Amaral AF, Porta M, Silverman DT, Milne RL, Kogevinas M, Rothman N, et al. Pancreatic cancer risk and levels of trace elements. Gut 2012; 61:1583-8.
19. Lee ET, Welty TK, Fabsitz R, Cowan LD, Le NA, Oopik AJ, et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol 1990;132:1141-55.
20. Scheer J, Findenig S, Goessler W, Francesconi KA, Howard B, Umans JG, et al. Arsenic species and selected metals in human urine: validation of HPLC/ICPMS and ICPMS procedures for a longterm population-based epidemiological study. Anal Methods 2012; 4:406-13.
21. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
22. Gamble MV, Hall MN. Relationship of creatinine and nutrition with arsenic metabolism. Environ Health Perspect 2012;120:A145-6.
23. Nermell B, Lindberg AL, Rahman M, Berglund M, Persson LA, El- Arifeen S, et al. Urinary arsenic concentration adjustment factors and malnutrition. Environ Res 2008;106:212-8.
24. Voinescu GC, Shoemaker M, Moore H, Khanna R, Nolph KD. The relationship between urine osmolality and specific gravity. Am J Med Sci 2002;323:39-42.
25. Chen CJ, Chuang YC, Lin TM, Wu HY. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 1985;45(11 Pt 2):5895-9.
26. Wu MM, Kuo TL, Hwang YH, Chen CJ. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 1989;130:1123-32.
27. Chen CL, Hsu LI, Chiou HY, Hsueh YM, Chen SY, Wu MM, et al. Ingested arsenic, cigarette smoking, and lung cancer risk: A follow-up study in arseniasis-endemic areas in Taiwan. JAMA 2004;292: 2984-90.
28. Wadhwa SK, Kazi TG, Chandio AA, Afridi HI, Kolachi NF, Kandhro GA, et al. Comparative study of liver cancer patients in arsenic exposed and non-exposed areas of Pakistan. Biol Trace Elem Res 2011;144:86-96.
29. Ryker SJ. Mapping arsenic in groundwater. Geotimes 2001;46:34-6.
30. Kurzius-Spencer M, O'Rourke MK, Hsu CH, HArtz V, HArris RB, Burgess JL, et al. Measured versus modeled dietary arsenic and relation to urinary arsenic excretion and total exposure. J Expo Sci Environ Epidemiol 2013;23:442-9.
31. Ferreccio C, Gonzalez PC, Milosavjlevic Stat V, Marshall GG, Sancha AM. Lung cancer and arsenic exposure in drinking water: A case- control study in northern Chile. Cad Saude Publica 1998;14 Suppl 3:193-8.
32. Smith AH, Marshall G, Liaw J, Yuan Y, Ferreccio C, Steinmaus C, et al. Mortality in young adults following in utero and childhood exposure to arsenic in drinking water. Environ Health Perspect 2012;120:1527-31.
33. Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon RL. Drinking water arsenic inUtah: A cohort mortality study. Environ Health Perspect 1999;107:359-65.
34. Medrano MA, Boix R, Pastor-Barriuso R, Palau M, Damian J, Ramis R, et al. Arsenic in public water supplies and cardiovascular mortality in Spain. Environ Res 2010;110:448-54.
35. Sohel N, Persson LA, Rahman M, Streatfield PK, Yunus M, Ekstrom EC, et al. Arsenic in drinking water and adult mortality: A populationbased cohort study in rural Bangladesh. Epidemiology 2009;20: 824-30.
36. Baastrup R, Sorensen M, Balstrom T, Frederiksen K, Larsen CL, Tjonneland A, et al. Arsenic in drinking-water and risk for cancer in Denmark. Environ Health Perspect 2008;116:231-7.
37. Mink PJ, Alexander DD, Barraj LM, Kelsh MA, Tsuji JS. Low-level arsenic exposure in drinking water and bladder cancer: A review and meta-analysis. Regul Toxicol Pharmacol 2008;52:299-310.
38. Heck JE, Andrew AS, Onega T, Rigas JR, JAckson BP, Karagas MR, et al. Lung cancer in a U.S. population with low to moderate arsenic exposure. Environ Health Perspect 2009;117:1718-23.
39. Waalkes MP, Liu J, Ward JM, Diwan BA. Animal models for arsenic carcinogenesis: inorganic arsenic is a transplacental carcinogen in mice. Toxicol Appl Pharmacol 2004;198:377-84.
40. Hughes MF. Arsenic toxicity and potential mechanisms of action. Toxicol Lett 2002;133:1-16.
41. Rossman TG. Mechanism of arsenic carcinogenesis: An integrated approach. Mutat Res 2003;533:37-65.
42. Martinez VD, Vucic EA, Adonis M, Gil L, Lam WL. Arsenic biotransformation as a cancer promoting factor by inducing DNA damage and disruption of repair mechanisms. Mol Biol Int 2011;2011: 718974.
43. Lu TH, Su CC, Chen YW, Yang CY, Wu CC, Hung DZ, et al. Arsenic induces pancreatic beta-cell apoptosis via the oxidative stress-regulated mitochondria-dependent and endoplasmic reticulum stress-triggered signaling pathways. Toxicol Lett 2011;201: 15-26.
44. Xue DB, Zhang WH, Yun XG, Song C, Zheng B, Shi XY, et al. Regulating effects of arsenic trioxide on cell death pathways and inflammatory reactions of pancreatic acinar cells in rats. Chin Med J (Engl) 2007; 120:690-5.
45. Davila-Esqueda ME, Morales JM, Jimenez-Capdeville ME, De la Cruz E, Falcon-Escobedo R, Chi-Ahumada E, et al. Low-level subchronic arsenic exposure from prenatal developmental stages to adult life results in an impaired glucose homeostasis. Exp Clin Endocrinol Diabetes 2011;119:613-7.
46. Axelson O, Dahlgren E, Jansson CD, Rehnlund SO. Arsenic exposure and mortality: A case-referent study from a Swedish copper smelter. Br J Ind Med 1978;35:8-15.
47. Ott MG, Holder BB, Gordon HL. Respiratory cancer and occupational exposure to arsenicals. Arch Environ Health 1974;29:250-5.
48. Rehman K, Naranmandura H. Arsenic metabolism and thioarsenicals. Metallomics 2012;4:881-92.
49. Chanan-Khan AA, Borrello I, Lee KP, Reece DE. Development of target-specific treatments in multiple myeloma. Br J Haematol 2010; 151:3-15.
50. Yedjou C, Tchounwou P, Jenkins J, McMurray R. Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol 2010;3:28.
51. Navas-Acien A, Umans JG, Howard BV, GoesslerW, Francesconi KA, Crainiceanu CM, et al. Urine arsenic concentrations and species excretion patterns in American Indian communities over a 10-year period: The Strong Heart Study. Environ Health Perspect 2009;117: 1428-33.
52. Bray F, Parkin DM. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer 2009;45:747-55.
53. Calderon RL, Hudgens E, Le XC, Schreinemachers D, Thomas DJ. Excretion of arsenic in urine as a function of exposure to arsenic in drinking water. Environ Health Perspect 1999;107:663-7.
54. Rivera-Nunez Z, Meliker JR, Meeker JD, Slotnick MJ, Nriagu JO. Urinary arsenic species, toenail arsenic, and arsenic intake estimates in a Michigan population with low levels of arsenic in drinking water. J Expo Sci Environ Epidemiol 2012;22:182-90.